Mantinex Flas

Memantine Hydrochloride, the active ingredient in Mantinex Flas, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of Alzheimer’s disease in adults.

GNH USA supplies Mantinex Flas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride acts on the glutamatergic pathway and is used in the management of dementia related to Alzheimer’s disease. - Alzheimer’s disease: improves cognition and functional abilities in patients with moderate to severe disease.

Memantine Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Hallucinations: visual or auditory disturbances. - Severe rash or skin peeling: signs of a serious cutaneous reaction.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function: assess kidney performance and adjust dose if needed. - Seizure history: monitor patients with prior seizures closely. - Hypertension: observe blood pressure as memantine may elevate it. - Psychiatric symptoms: watch for new or worsening confusion or hallucinations. - Discontinuation: avoid abrupt stopping; taper if clinically appropriate. - Store at ambient temperature: keep in the original container, protect from moisture.

Memantine Hydrochloride can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists: additive effects can raise risk of severe side effects.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil): may alter cognitive outcomes. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Antihypertensives: monitor blood pressure for additive rise.